RNAi-combined nano-chemotherapeutics to tackle resistant tumors

Drug Discovery Today

Volumn 21, Issue 11, 2016, Pages 1761-1774

  Tekade, Rakesh Kumar ^a   Tekade, Muktika ^b   Kesharwani, Prashant ^c   D'Emanuele, Antony ^d  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER AHMEDABAD   (India)

^b TIT College of Pharmacy   (India)

^c WAYNE STATE UNIVERSITY   (United States)

^d DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHITOSAN; DENDRIMER; LIPID; MICRORNA; NANOCARRIER; NANOPARTICLE; POLYETHYLENEIMINE; POLYMER; SMALL INTERFERING RNA;

CANCER RESISTANCE; CANCER THERAPY; COMBINATION CHEMOTHERAPY; DRUG DELIVERY SYSTEM; HUMAN; NANOTECHNOLOGY; NONHUMAN; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; DRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOTECHNOLOGY; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84979008645     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.06.029     Document Type: Review

References (95)

1. 1 Moeendarbari, S., et al. Theranostic nanoseeds for efficacious internal radiation therapy of unresectable solid tumors. Sci. Rep., 6, 2016, 20614.
2. 2 Chen, W., Yang, L., Targeted delivery with imaging assessment of siRNA expressing nanocassettes into cancer. Methods Mol. Biol. 1372 (2016), 49–59.
3. 3 Meng, L.H., Zheng, X.S., Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol. Sin. 36 (2015), 1163–1169.
4. 4 Huang, C.W., et al. Hollow gold nanoparticals as biocompatible radiosensitizer: an in vitro proof of concept study. J. Nano Res. 32 (2015), 106–112.
5. 5 Ghanghoria, R., et al. Luteinizing hormone-releasing hormone peptide tethered nanoparticulate system for enhanced antitumoral efficacy of paclitaxel. Nanomedicine (Lond.) 11 (2016), 797–816.
6. 6 Stojanovska, V., et al. Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. Am. J. Physiol. Gastrointest. Liver Physiol. 308 (2015), G223–G232.
7. 7 Arnason, T., Harkness, T., Development, maintenance, and reversal of multiple drug resistance: at the crossroads of TFPI1, ABC transporters, and HIF1. Cancers (Basel) 7 (2015), 2063–2082.
8. 8 Crowley, E., Callaghan, R., Multidrug efflux pumps: drug binding – gates or cavity?. FEBS J. 277 (2010), 530–539.
9. 9 Creixell, M., Peppas, N.A., Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 7 (2012), 367–379.
10. 10 Kayat, J., et al. Pulmonary toxicity of carbon nanotubes: a systematic report. Nanomedicine 7 (2011), 40–49.
11. 11 Tekade, R.K., et al. siRNA therapy, challenges and underlying perspectives of dendrimer as delivery vector. Curr. Pharm. Des. 21 (2015), 4614–4636.
12. 12 Maheshwari, R., et al. Nanocarriers assisted siRNA gene therapy for the management of cardiovascular disorders. Curr. Pharm. Des. 21 (2015), 4427–4440.
13. 13 Tekade, R.K., Editorial: contemporary siRNA therapeutics and the current state-of-art. Curr. Pharm. Des. 21 (2015), 4527–4528.
14. 14 Sharma, P.A., et al. Nanomaterial based approaches for the diagnosis and therapy of cardiovascular diseases. Curr. Pharm. Des. 21 (2015), 4465–4478.
15. 15 Mitchell, E.P., Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clin. Colorectal Cancer 12 (2013), 73–85.
16. 16 Wan, B., et al. Single-walled carbon nanotubes and graphene oxides induce autophagosome accumulation and lysosome impairment in primarily cultured murine peritoneal macrophages. Toxicol. Lett. 221 (2013), 118–127.
17. 17 Xu, J., et al. Non-condensing polymeric nanoparticles for targeted gene and siRNA delivery. Int. J. Pharm. 427 (2012), 21–34.
18. 18 Kim, Y.M., et al. An injectable cell penetrable nano-polyplex hydrogel for localized siRNA delivery. Biomaterials 34 (2013), 4493–4500.
19. 19 Guzman-Villanueva, D., et al. Formulation approaches to short interfering RNA and MicroRNA: challenges and implications. J. Pharm. Sci. 101 (2012), 4046–4066.
20. 20 Aburahma, M.H., Abdelbary, G.A., Novel diphenyl dimethyl bicarboxylate provesicular powders with enhanced hepatocurative activity: preparation, optimization, in vitro/in vivo evaluation. Int. J. Pharm. 422 (2012), 139–150.
21. 21 Kleinman, M.E., et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452 (2008), 591–597.
22. 22 Youngren, S.R., et al. STAT6 siRNA matrix-loaded gelatin nanocarriers: formulation, characterization, and ex vivo proof of concept using adenocarcinoma cells. Biomed. Res. Int., 2013, 2013, 858946.
23. 23 Gandhi, N.S., et al. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J. Control. Release 194 (2014), 238–256.
24. 24 Maheshwari, R.G.S., et al. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm. J. 20 (2012), 161–170.
25. 25 Gajbhiye, V., et al. Dendrimers as therapeutic agents: a systematic review. J. Pharm. Pharmacol. 61 (2009), 989–1003.
26. 26 Gajbhiye, V., et al. PEGylated PPI dendritic architectures for sustained delivery of H2 receptor antagonist. Eur. J. Med. Chem. 44 (2009), 1155–1166.
27. 27 Tekade, R.K., et al. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J. Microencapsul. 26 (2009), 287–296.
28. 28 Dhakad, R.S., et al. Cancer targeting potential of folate targeted nanocarrier under comparative influence of tretinoin and dexamethasone. Curr. Drug Deliv. 10 (2013), 477–491.
29. 29 Dwivedi, P., et al. Nanoparticulate carrier mediated intranasal delivery of insulin for the restoration of memory signaling in Alzheimer's disease. Curr. Nanosci. 9 (2013), 46–55.
30. 30 Thakur, S., et al. The effect of polyethylene glycol spacer chain length on the tumor-targeting potential of folate-modified PPI dendrimers. J. Nanoparticle Res. 15 (2013), 1–16.
31. 31 Kesharwani, P., et al. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 33 (2012), 7138–7150.
32. 32 Prajapati, R.N., et al. Dendimer-mediated solubilization, formulation development and in vitro–in vivo assessment of piroxicam. Mol. Pharm. 6 (2009), 940–950.
33. 33 Park, S., et al. Preparation and characterization of nonaarginine-modified chitosan nanoparticles for siRNA delivery. Carbohydr. Polym. 92 (2013), 57–62.
34. 34 Kesharwani, P., et al. Generation dependent safety and efficacy of folic acid conjugated dendrimer based anticancer drug formulations. Pharm. Res. 32 (2015), 1438–1450.
35. 35 Jain, N.K., Tekade, R.K., Dendrimers for enhanced drug solubilization. Douroumis, D., Fahr, A., (eds.) Drug Delivery Strategies for Poorly Water-Soluble Drugs, 2013, John Wiley & Sons, 373–409.
36. 36 Mody, N., et al. Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug delivery potential. AAPS PharmSciTech 15 (2014), 388–399.
37. 37 Tekade, R.K., et al. Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. J. Drug Target 16 (2008), 758–772.
38. 38 Huang, H.Y., et al. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. J. Biomed. Mater. Res. A 97 (2011), 330–338.
39. 39 Boussif, O., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 7297–7301.
40. 40 Jang, Y.L., et al. Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression. Int. J. Pharm. 434 (2012), 488–493.
41. 41 Kumar, R., et al. In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. J. Biomed. Nanotechnol. 7 (2011), 325–333.
42. 42 Orson, F.M., et al. Genetic immunization with lung-targeting macroaggregated polyethyleneimine–albumin conjugates elicits combined systemic and mucosal immune responses. J. Immunol. 164 (2000), 6313–6321.
43. 43 Cheng, D., et al. Multifunctional nanocarrier mediated co-delivery of doxorubicin and siRNA for synergistic enhancement of glioma apoptosis in rat. Biomaterials 33 (2012), 1170–1179.
44. 44 Maheshwari, R.G.S., et al. Chitosan encrusted nonionic surfactant based vesicular formulation for topical administration of ofloxacin. Sci. Adv. Mater. 7 (2015), 1163–1176.
45. 45 Tekade, R.K., et al. Designing hybrid onconase nanocarriers for mesothelioma therapy: a Taguchi orthogonal array and multivariate component driven analysis. Mol. Pharm. 11 (2014), 3671–3683.
46. 46 Tekade, R.K., et al. Dendrimer-stabilized smart-nanoparticle (DSSN) platform for targeted delivery of hydrophobic antitumor therapeutics. Pharm. Res. 32 (2015), 910–928.
47. 47 Wei, W., et al. Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials 34 (2013), 3912–3923.
48. 48 Meng, H., et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 4 (2010), 4539–4550.
49. 49 Gumulec, J., et al. Modulation of induced cytotoxicity of Doxorubicin by using apoferritin and liposomal cages. Int. J. Mol. Sci. 15 (2014), 22960–22977.
50. 50 Meng, H., et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 7 (2013), 994–1005.
51. 51 Kooijmans, S.A., et al. Exosome mimetics: a novel class of drug delivery systems. Int. J. Nanomed. 7 (2012), 1525–1541.
52. 52 Taratula, O., et al. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target 19 (2011), 900–914.
53. 53 Kesharwani, P., et al. Dendrimer generational nomenclature: the need to harmonize. Drug Discov. Today, 20, 2015 497-479.
54. 54 Tekade, R.K., Chougule, M.B., Formulation development and evaluation of hybrid nanocarrier for cancer therapy: taguchi orthogonal array based design. BioMed. Res. Int. 2013, 2013, 712678.
55. 55 Tekade, R.K., et al. Dendrimers in oncology: an expanding horizon. Chem. Rev. 109 (2009), 49–87.
56. 56 Biswas, S., et al. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials 34 (2013), 1289–1301.
57. 57 Kaneshiro, T.L., et al. Synthesis, characterization, and gene delivery of poly-L-lysine octa(3-aminopropyl)silsesquioxane dendrimers: nanoglobular drug carriers with precisely defined molecular architectures. Mol. Pharm. 4 (2007), 759–768.
58. 58 Kaneshiro, T.L., Lu, Z.R., Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 30 (2009), 5660–5666.
59. 59 Aldwell, F.E., et al. Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice. Infect. Immun. 71 (2003), 101–108.
60. 2+ gradient demonstrates improved pharmacokinetics, drug delivery and antitumor efficacy. J. Control. Release 161 (2012), 142–149.
61. 61 Yang, Y.Y., et al. Polymeric core-shell nanoparticles for therapeutics. Clin. Exp. Pharmacol. Physiol. 33 (2006), 557–562.
62. 62 Zhang, Y., et al. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol. Ther. 21 (2013), 1559–1569.
63. 63 Zheng, C., et al. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy. Biomaterials 34 (2013), 3431–3438.
64. 64 Zou, S., et al. Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin. Int. J. Nanomed. 7 (2012), 3823–3835.
65. 65 Hiwale, P., et al. In vitro release of lysozyme from gelatin microspheres: effect of cross-linking agents and thermoreversible gel as suspending medium. Biomacromolecules 12 (2011), 3186–3193.
66. 66 Roughley, P.J., Helix formation. Its involvement in the formation of gel structures. Trans. Ophthalmol. Soc. UK 95 (1975), 369–371.
67. 67 Babu, A., et al. Gelatin nanocarrier enables efficient delivery and phototoxicity of hypocrellin B against a mice tumour model. J. Biomed. Nanotechnol. 8 (2012), 43–56.
68. 68 Patil, Y.B., et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31 (2010), 358–365.
69. 69 Armour, C., et al. Mediators on human airway smooth muscle. Clin. Exp. Pharmacol. Physiol. 24 (1997), 269–272.
70. 70 Beauchesne, P.R., et al. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev. Ind. Pharm. 33 (2007), 211–220.
71. 71 Nakamura, K., et al. A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol. Ther. 19 (2011), 2040–2047.
72. 72 Liao, J., et al. Combined cancer photothermal-chemotherapy based on doxorubicin/gold nanorod-loaded polymersomes. Theranostics 5 (2015), 345–356.
73. 73 Pangburn, T.O., et al. Targeted polymersome delivery of siRNA induces cell death of breast cancer cells dependent upon Orai3 protein expression. Langmuir 28 (2012), 12816–12830.
74. 74 Kumar, A., et al. ROP and ATRP fabricated dual targeted redox sensitive polymersomes based on pPEGMA-PCL-ss-PCL-pPEGMA triblock copolymers for breast cancer therapeutics. ACS Appl. Mater. Interfaces 7 (2015), 9211–9227.
75. 75 Kim, H.O., et al. A biodegradable polymersome containing Bcl-xL siRNA and doxorubicin as a dual delivery vehicle for a synergistic anticancer effect. Macromol. Biosci. 13 (2013), 745–754.
76. 76 Kim, Y., et al. Polymersome delivery of siRNA and antisense oligonucleotides. J. Control. Release 134 (2009), 132–140.
77. 77 Meyer, O., et al. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J. Biol. Chem. 273 (1998), 15621–15627.
78. 78 Arias, J.L., Liposomes in drug delivery: a patent review (2007–present). Expert Opin. Ther. Pat. 23 (2013), 1399–1414.
79. 79 Yang, T., et al. Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo. Theranostics 4 (2014), 1096–1111.
80. 80 Chen, Y., et al. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol. Pharm. 6 (2009), 696–705.
81. 81 Chen, Y., et al. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J. Biol. Chem. 285 (2010), 22639–22650.
82. 82 Zaupa, A., et al. Influence of tyrosine-derived moieties and drying conditions on the formation of helices in gelatin. Biomacromolecules 12 (2011), 75–81.
83. 83 Amiji, M.M., Nanomedicine for cancer therapy. Pharm. Res. 28 (2011), 181–186.
84. 84 Kang, S.H., et al. Cationic liposomal co-delivery of small interfering RNA and a MEK inhibitor for enhanced anticancer efficacy. Pharm. Res. 28 (2011), 3069–3078.
85. 85 Hao, Z., et al. Preparation and characterization of lung-targeting ceftiofur-loaded gelatin microspheres. Drug Dev. Ind. Pharm. 37 (2011), 1422–1428.
86. 86 Zhao, Y.Z., et al. Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy. Acta Diabetol. 49 (2012), 315–325.
87. 87 Kim, H.R., et al. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol. Pharm. 5 (2008), 622–631.
88. 88 Giraudier, S., et al. Influence of weak and covalent bonds on formation and hydrolysis of gelatin networks. Biomacromolecules 5 (2004), 1662–1666.
89. 89 Yancopoulos, G.D., et al. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000), 242–248.
90. 90 Shim, G., et al. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. J. Control. Release 155 (2011), 60–66.
91. 91 Robinson, C.J., Stringer, S.E., The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114 (2001), 853–865.
92. 92 Ammit, A.J., et al. Mast cell numbers are increased in the smooth muscle of human sensitized isolated bronchi. Am. J. Respir. Crit. Care Med. 155 (1997), 1123–1129.
93. 93 Burnett, J.C., et al. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6 (2011), 1130–1146.
94. 94 Davidson, B.L., McCray, P.B. Jr., Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12 (2011), 329–340.
95. 95 Whitehead, K.A., et al. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8 (2009), 129–138.